hotspot -WSS

hotspot

author：comprehensive 2025-09-14 22:00:49 - browse：8313

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout LOUD podcast: The Sarepta saga, decoding biotech hype

leisure time

WSS

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Inari Medical to buy amputation prevention company LimFlow

Leqembi, other new Alzheimer’s drugs require better biomarkers

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Inari Medical to buy amputation prevention company LimFlow

hotspot

hotspot

explore

Sports medicine is finally prioritizing gender equality

The health care issue Democrats can’t solve: hospital reform

Affirmative action in medical school literally saved lives

Gene therapy’s promise and the high cost of hope

Drug repurposing or repositioning? The language matters

NIH fellows want a pay raise. Will that mean less money for grants?

Sports medicine is finally prioritizing gender equality

Kidney transplant patients stopped immunosuppressants in trial

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: ESMO highlights & Roivant's big deal

hotspot

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Inari Medical to buy amputation prevention company LimFlow

Coloradans with cystic fibrosis could lose access to Trikafta

Life sciences investors close nearly $6 billion in new funds

Medicare must police algorithms in Medicare Advantage, Dems say

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

leisure time

focus

entertainment

knowledge